These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38453593)

  • 21. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience.
    Huang X; Hapgood K; Allan K; Pruette C; Goswami E
    Pediatr Transplant; 2024 Feb; 28(1):e14611. PubMed ID: 37735900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
    Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
    Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study.
    Moal V; Grimbert P; Beauvais A; Dubel L; Le Meur Y
    Ann Transplant; 2019 Sep; 24():517-526. PubMed ID: 31477681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience.
    Slatinska J; Rohal T; Wohlfahrtova M; Viklicky O
    Transplant Proc; 2013 May; 45(4):1491-6. PubMed ID: 23726604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients.
    Fontova P; Colom H; Rigo-Bonnin R; Bestard O; Vidal-Alabró A; van Merendonk LN; Cerezo G; Polo C; Montero N; Melilli E; Manonelles A; Meneghini M; Coloma A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Clin Pharmacol Ther; 2021 Jul; 110(1):238-247. PubMed ID: 33626199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.
    Anft M; Zgoura P; Skrzypczyk S; Dürr M; Viebahn R; Westhoff TH; Stervbo U; Babel N
    Front Transplant; 2024; 3():1405070. PubMed ID: 39386200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients.
    Choi D; Thaker S; West-Thielke P; Elmasri A; Chan C
    Eur J Gastroenterol Hepatol; 2021 Aug; 33(8):1124-1128. PubMed ID: 34213506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study.
    Dumortier J; Duvoux C; Dubel L; Bazin F; Houssel-Debry P
    Ann Transplant; 2019 Aug; 24():506-516. PubMed ID: 31451681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.
    van Zyl JS; Sam T; Clark DM; Felius J; Doss AK; Kerlee KR; Cheung ZO; Martits-Chalangari K; Jamil AK; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA
    Clin Transplant; 2021 Dec; 35(12):e14487. PubMed ID: 34529289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.
    Zaltzman JS; Lai V; Schulz MZ; Moon KH; Cherney DZ
    Transpl Int; 2014 Dec; 27(12):1294-302. PubMed ID: 25160518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion From a Twice-Daily to a Once-Daily Tacrolimus Formulation in Kidney Transplant Recipients.
    Kamińska D; Poznański P; Kuriata-Kordek M; Zielińska D; Mazanowska O; Kościelska-Kasprzak K; Krajewska M
    Transplant Proc; 2020 Oct; 52(8):2288-2293. PubMed ID: 32247597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Envarsus XR® pharmacokinetics in adolescents post-kidney transplantation - A pilot study.
    ElChaki R; Ettenger R; Lee S; Chen L; Gales B; Srivastava R; Pearl M
    Pediatr Transplant; 2023 May; 27(3):e14480. PubMed ID: 36732080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year outcomes of de novo tacrolimus extended-release tablets (LCPT) compared to twice-daily tacrolimus in adult heart transplantation.
    Alam A; van Zyl JS; Patel R; Jamil AK; Felius J; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA; Sam T
    Transpl Immunol; 2024 Apr; 83():102009. PubMed ID: 38325525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients.
    Baccarani U; Velkoski J; Pravisani R; Adani GL; Lorenzin D; Cherchi V; Falzone B; Baraldo M; Risaliti A
    Transplant Proc; 2019 Nov; 51(9):2971-2973. PubMed ID: 31607620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland.
    Bonani M; Balaphas A; Bedino G; Bühler L; Dutkowski P; Fausch K; Gluderer S; Graf N; Hirt-Minkowski P; Müllhaupt B; Schönholzer C; Schulz MM; Venzin R; Wüthrich RP
    Swiss Med Wkly; 2021 Feb; 151():w20453. PubMed ID: 33638353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Administration of Once-Daily MeltDose
    Willuweit K; Frey A; Hörster A; Saner F; Herzer K
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33396492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.